Pfizer and Sanofi "on the list" will the generic drug market be reshuffled?

With 17 more varieties, the generic drug market is about to change.

Compared with high-priced original research drugs, generic drugs can greatly reduce the burden of patients' medication and the burden of the National Medical Insurance Fund.

This is not the first time that the list of encouraged generic drugs has been announced.

In addition to the 17 drugs in the second batch, 50 drugs have been included in the list of encouraged generic drugs.

Encourage the introduction and expansion of the generic drug catalog, aiming to encourage more manufacturers to produce and compete, shorten the application time, optimize the application path, to a certain extent alleviate the supply of clinically necessary, effective, and shortage drugs, and benefit more urgent needs Patients taking medication.

01 "The guiding light" of generic drug companies

The second list of encouraged generic drugs was announced, including arformoterol, fluticasone furoate, vilanterol, clevidipine, eligrostat, perampanel, etc.

Why develop a catalog to encourage generic drugs?

Generic drugs have the same therapeutic effects as the original drugs, but are relatively inexpensive and have become a life-saving straw for some patients.

Obviously, as the "fast forward button" is pressed for the listing of generic drugs, not only the majority of patients will benefit, but also generic drug manufacturers and the pharmaceutical industry.

Compared with the 19 varieties in the recommended list previously released, the two drugs, brimonidine, timolol and olaparib, were not selected in the official list.

02 Encourage imitation to become normal

More than 95% of drug approvals in my country are generic drugs.

In fact, as early as April 2018, the "Opinions on Reforming and Improving the Supply Guarantee and Use Policy of Generic Drugs" clarified the scope of drugs that encourage generic drugs: drugs that are clinically necessary, have definite efficacy, and are in short supply.

In December 2018, the "Notice on Issuing the Work Plan for Accelerating the Implementation of the Policy on the Supply and Use of Generic Drugs", once again clarified the 7 key tasks for accelerating the implementation of the policy on the supply and use of generic drugs, and required the timely release of a catalog of drugs that encourage generics .

Obviously, it is a foregone conclusion to encourage normalization and addition of the generic drug catalogue.

On the other hand, encouraging generic drugs to replace original research drugs can greatly reduce the burden on medical insurance departments.

Under the "blessing" of the consistency evaluation, the generic drugs have achieved the same curative effect as the original drugs.